NET ASSET VALUE – 31 August 2025
On the 31 August 2025 Flerie AB's Net Asset Value (NAV) was SEK 3,899 million and NAV per share was SEK 50.34.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Prokarium | 42% | 448 | 5.78 | 11.5% |
| Xspray Pharma | 18% | 308 | 3.98 | 7.9% |
| Empros Pharma | 79% | 204 | 2.64 | 5.2% |
| Atrogi | 44% | 197 | 2.54 | 5.0% |
| KAHR Medical | 30% | 179 | 2.31 | 4.6% |
| Lipum | 57% | 157 | 2.03 | 4.0% |
| Xintela | 59% | 148 | 1.91 | 3.8% |
| Goldcup 37076 (previously Toleranzia) | 100% | 131 | 1.69 | 3.4% |
| Microbiotica | 10% | 128 | 1.65 | 3.3% |
| Geneos Therapeutics | 12% | 91 | 1.18 | 2.3% |
| Mendus | 23% | 86 | 1.11 | 2.2% |
| AnaCardio | 13% | 79 | 1.02 | 2.0% |
| EpiEndo Pharmaceuticals | 9% | 55 | 0.71 | 1.4% |
| Vitara Biomedical | 11% | 47 | 0.61 | 1.2% |
| Buzzard Pharmaceuticals | 14% | 32 | 0.41 | 0.8% |
| Egetis Therapeutics | 1% | 25 | 0.32 | 0.6% |
| Amarna Therapeutics | 58% | 11 | 0.14 | 0.3% |
| Strike Pharma | 18% | 11 | 0.14 | 0.3% |
| Alder Therapeutics | 30% | 8 | 0.10 | 0.2% |
| Synerkine Pharma | 44% | 0 | 0.00 | 0.0% |
| Sixera Pharma | 35% | 0 | 0.00 | 0.0% |
| Total | 2,344 | 30.26 | 60.1% | |
| Commercial Growth | ||||
| NorthX Biologics | 61% | 202 | 2.61 | 5.2% |
| Symcel | 30% | 192 | 2.48 | 4.9% |
| Chromafora | 30% | 73 | 0.94 | 1.9% |
| Nanologica | 44% | 56 | 0.72 | 1.4% |
| Frontier Biosolutions | 2% | 18 | 0.24 | 0.5% |
| Bohus Biotech | 45% | 17 | 0.22 | 0.4% |
| Total | 558 | 7.20 | 14.3% | |
| Limited Partnerships, total | 106 | 1.37 | 2.7% | |
| Assets related to Portfolio companies | 301 | 3.89 | 7.7% | |
| Other assets and liabilities | 590 | 7.62 | 15.1% | |
| Net Asset Value | 3,899 | 50.34 | 100.0 | |